← Leaderboards
H Pitot
Mayo Clinic Coll Of Medicine, Rochester
$0
Attributed
$0
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 2
By mechanism
M01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Alex A Adjei$13,436,633
- Lieping Chen$19,852,609
- Neil E Kay$14,251,394
- Charles Erlichman$15,466,165
- Robert B. Jenkins$6,438,057
Others in their field
Top investigators on “Pharmacokinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$237,100,725
- Constance Ann Benson · University Of California, San Diego$151,891,628
- Richard L Schilsky · University Of Chicago$114,474,127
- Ronald T Mitsuyasu · University Of California Los Angeles$105,970,100
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,574,471
- Myron S Cohen · Family Health International$91,263,426
Research focus
PharmacokineticsClinical ResearchClinical Trial Phase IDosageDrug Screening /EvaluationHuman SubjectNeoplasm /Cancer ChemotherapyOral AdministrationAntineoplastic AntibioticsHuman Therapy EvaluationIrinotecanNeoplasm /CancerDrug Adverse EffectAlkylating Agents
Grant awards (6)
PHASE I TRIAL OF BIZELESIN IN PATIENTS WITH ADVANCED CANCER$0
M01 · FY2002 · RR
ORALLY ADMINISTERED IRINOTECAN HC1 IN PATIENTS W/ ADVANCED SOLID TUMORS$0
M01 · FY2002 · RR
PHASE I TRIAL OF BIZELESIN IN PATIENTS WITH ADVANCED CANCER$0
M01 · FY2001 · RR
ORALLY ADMINISTERED IRINOTECAN HC1 IN PATIENTS W/ ADVANCED SOLID TUMORS$0
M01 · FY2001 · RR
PHASE I TRIAL OF BIZELESIN IN PATIENTS WITH ADVANCED CANCER$0
M01 · FY2000 · RR
ORALLY ADMINISTERED IRINOTECAN HC1 IN PATIENTS W/ ADVANCED SOLID TUMORS$0
M01 · FY2000 · RR